Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance
Advanced Science · 2025
DOI: 10.1002/advs.202417714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Junjiang Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Bevacizumab, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Antiangiogenic therapies, such as bevacizumab, are among the causes of cancer‐related death in patients with colorectal cancer (CRC) with liver metastasis. Delivering siRNAs via primary cell originating from primary cells is a promising method for targeting CRC liver metastasis and drug resistance. Here, it is found that the expression of CCL24 is significantly upregulated in tumor tissues at the CRC liver metastasis site. In addition, CCL24 is significantly upregulated in tumor tissues from bevacizumab‐resistant patients. CCL24 promotes the formation of inflammatory tumor‐associated fibroblast subsets in the CRC liver metastasis microenvironment and induces resistance to bevacizumab therapy. Based on these results, a primary cell‐derived extracellular vehicle delivery system is designed for the simultaneous delivery of siRNAs targeting CCL24 in the tumor microenvironment (TME). Downregulation of CCL24 in the TME by delivering bioengineered extracellular vehicles significantly increased sensitivity to antiangiogenic therapy in a CRC mouse model. A novel therapeutic target is identified for patients with CRC with liver metastasis and suggested a possible therapeutic alternative for patients with CRC with resistance to antiangiogenic therapy and distant metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510000, China.
- School of Medicine, South China University of Technology, Guangzhou, 510006, China.
- Department of General Surgery, Guangdong Provincial People's Hospital Ganzhou Hospital (Ganzhou Municipal Hospital), Ganzhou, 341000, China.
- Department of General Surgery, Guangdong Provincial People's Hospital Heyuan Hospital, Heyuan, 517000, China.
ORCID-Profile: Xueqing Yao
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, J., Liu, C., Wang, P., Liu, Z., Hu, W., Lv, Z., Huang, C., & Yao, X. (2025). Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance. Advanced Science. https://doi.org/10.1002/advs.202417714
Vancouver
Wang J, Liu C, Wang P, Liu Z, Hu W, Lv Z, et al. Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance. Advanced Science. 2025. doi:10.1002/advs.202417714
BibTeX
@article{Wang2025,
author = {Wang, Junjiang and Liu, Chunsheng and Wang, Ping and Liu, Zhiyuan and Hu, Weixian and Lv, Zejian and Huang, Chengzhi and Yao, Xueqing},
title = {Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202417714}
}
EUVIMED